Outpouring of love counters sign of hate on Ojai peace sign
Photo by Fern Barishman
A ubiquitous pink peace sign in Ojai, created by Fern Barishman s neighbor Lou Mora, was given to her by friend Brian Berman. It replaces the peace sign in front of Barishman s home on Ojai s Ventura Street that was defaced with a spraypainted backward swastika, obscenity and racial epithet sometime overnight between Feb. 19 and Feb. 20.
Ojai Valley News editor
Who ever spraypainted a backward swastika, racial epithet and obscenity on a pink peace sign on Ojai’s Ventura Street during the night from Feb. 19 to the morning of Feb. 20 probably had no idea that act of hate would prompt such an outpouring of love.
Share January 25, 2021, 9:29 PM
The columnist, a Los Angeles freelancer, is a former Detroit News business reporter who blogs at Starkman Approved.
By Eric Starkman The
inevitable tragedy Beaumont Health chairman John Lewis and Michigan Attorney General Dana Nessel were warned about occurred last Thursday in the early afternoon: A 51-year-old man walked into the colonoscopy suite at Beaumont’s flagship Royal Oak hospital at 13 and Woodward thinking he’d be undergoing a routine screening and heading home a few hours later. Instead, the patient, the sole caregiver for his elderly mother, wound up in Beaumont’s basement morgue. Veteran employees at Beaumont s Royal Oak campus are both angered and saddened by the death, which they say was an expected medical catastrophe resulting from COO Carolyn Wilson’s money-saving decision last April to award Texas-based NorthStar Anesthesia, a controversial low-cost outsourcing firm, a contract to manage anesthe
Search jobs 20-Dec-2020 Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer
GAITHERSBURG, Md. and SUZHOU BIOBAY, China, Dec. 20, 2020 /PRNewswire/ Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced positive efficacy and safety results from a Phase 2a clinical study of the company s lead drug candidate, STP705, for treatment of squamous cell skin cancer.
The open label, dose escalation study was designed to evaluate the efficacy and safety of intralesional injection of STP705 in adult patients with cutaneous squamous cell carcinoma in situ (isSCC, Bowen s disease), confirmed with biopsy samples. The objective was to determine the safe and effective recommended dose of STP705 for the treatment of isSCC, as well as to analyze biomarkers common to isSCC formation pathways
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer
December 20, 2020 GMT
Sirnaomics Company Logo (PRNewsfoto/Sirnaomics, Inc.)
GAITHERSBURG, Md. and SUZHOU BIOBAY, China, Dec. 20, 2020 /PRNewswire/ Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced positive efficacy and safety results from a Phase 2a clinical study of the company’s lead drug candidate, STP705, for treatment of squamous cell skin cancer.
The open label, dose escalation study was designed to evaluate the efficacy and safety of intralesional injection of STP705 in adult patients with cutaneous squamous cell carcinoma in situ (isSCC, Bowen’s disease), confirmed with biopsy samples. The objective was to determine the safe and effective recommended dose of S